Cost Insights: Breaking Down Merck & Co., Inc. and Bio-Techne Corporation's Expenses

Cost Dynamics: Merck vs. Bio-Techne's Financial Strategies

__timestampBio-Techne CorporationMerck & Co., Inc.
Wednesday, January 1, 201410635200016768000000
Thursday, January 1, 201514496900014934000000
Friday, January 1, 201616236400013891000000
Sunday, January 1, 201718846200012775000000
Monday, January 1, 201821085000013509000000
Tuesday, January 1, 201924051500014112000000
Wednesday, January 1, 202025549700013618000000
Friday, January 1, 202129818200013626000000
Saturday, January 1, 202234910300017411000000
Sunday, January 1, 202336688700016126000000
Monday, January 1, 2024389335000
Loading chart...

Cracking the code

Unveiling Cost Dynamics: Merck & Co., Inc. vs. Bio-Techne Corporation

In the ever-evolving landscape of the pharmaceutical and biotechnology sectors, understanding cost structures is pivotal. This analysis delves into the cost of revenue trends for two industry giants: Merck & Co., Inc. and Bio-Techne Corporation, from 2014 to 2023.

Merck & Co., Inc., a stalwart in the pharmaceutical industry, has seen its cost of revenue fluctuate, peaking in 2014 and 2022. Notably, 2022 marked a significant increase, with costs rising by approximately 36% compared to 2017. Meanwhile, Bio-Techne Corporation, a leader in biotechnology, has experienced a steady upward trajectory in its cost of revenue, with a remarkable 266% increase from 2014 to 2023.

While Merck's data for 2024 remains elusive, Bio-Techne continues its upward trend, underscoring its growth strategy. This comparative analysis offers a window into the financial strategies shaping these industry leaders.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025